A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma
Clinical trial NCT06178601 · UNKNOWN
Trial details
- NCT number
- NCT06178601
- Sponsor
- Shanxi Province Cancer Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-08-03
- Primary completion
- 2024-09-01
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.